Gyros AB collaborating with independent cancer research organization to evaluate new technology.

18-Feb-2002

Gyros AB announced today that the first application for Gyros technology is under evaluation by the Ludwig Institute for Cancer Research. The work is being carried out in collaboration with Professor Ulf Hellman, a Member of the Ludwig Institute.

The soon-to-be-launched application from Gyros is designed to improve and streamline sample preparation prior to analysis by MALDI mass spectrometry, a technique used for protein identification not only at the Ludwig Institute, but throughout the world of research and drug discovery.

Professor Hellman explained the reason for his interest: “In our Protein Structure Group we need to identify low abundance proteins and we work with minute amounts of sample, often only a few nanograms are available. We have to specialize in sample preparation techniques not only because we handle such small amounts, but also because any improvement in sample preparation can lead to an increase in sensitivity for the final analysis.”

Excellent sample preparation is crucial to achieve highest sensitivity and a high success rate for identification by MALDI mass spectrometry. The microfluidic solution from Gyros integrates several preparation steps into one automated process and achieves sensitivity levels close to the detection limit of a MALDI mass spectrometer. Multiple samples can be processed in parallel within a microlaboratory in the form of a CD.

Professor Hellman continued, “This work will be an interesting challenge between man and machine. As anyone working with MALDI-ToF mass spectrometry knows, the most precious samples are prepared individually and with great care to ensure the highest sensitivity. To achieve a similar result on a fully automated system would be a major step forward in productivity for our lab.”

“The Protein Structure Group at the Ludwig Institute works with the same techniques and has similar goals to those working in the proteomics area of drug discovery, the main target group for our new system,” explained Per Sjöberg, Executive Vice President Commercial Operations at Gyros,” Professor Hellman’s work will be of great benefit to us and is a perfect complement to testing already in progress at the proteomics company, Ace BioSciences, in Denmark. We are extremely confident of a successful launch within a matter of months.”


Enquiries:
For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
www.zymecommunications.com


Notes to editors:
About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.